Tixagevimab/cilgavimab at a dose of 150/150 mg is recommended for individuals with advanced or untreated HIV infection, defined as having CD4 counts < 200 cells/mm3 or a history of an AIDS-defining condition without immune reconstitution or clinical manifestations of symptomatic HIV [81]. This evidence concerns the gene CD4 and AIDS.